Login to Your Account

Orbus starts phase III brain cancer trial with repurposed eflornithine

By Jennifer Boggs
Managing Editor

Monday, September 26, 2016

Two established biopharma execs and a repurposed drug with a wealth of safety data and promising efficacy in a randomized study netted startup Orbus Therapeutics Inc. $32.5 million in series A funding last year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription